NEXGEL, Inc. (NXGL)
NASDAQ: NXGL · Real-Time Price · USD
0.5911
-0.0336 (-5.38%)
At close: Apr 2, 2026, 4:00 PM EDT
0.6087
+0.0176 (2.98%)
After-hours: Apr 2, 2026, 4:21 PM EDT
NEXGEL Revenue
In the year 2025, NEXGEL had annual revenue of $11.42M with 31.46% growth. NEXGEL had revenue of $2.80M in the quarter ending December 31, 2025, a decrease of -8.06%.
Revenue (ttm)
$11.42M
Revenue Growth
+31.46%
P/S Ratio
0.44
Revenue / Employee
$601,105
Employees
19
Market Cap
4.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.42M | 2.73M | 31.46% |
| Dec 31, 2024 | 8.69M | 4.60M | 112.47% |
| Dec 31, 2023 | 4.09M | 2.04M | 99.66% |
| Dec 31, 2022 | 2.05M | 497.00K | 32.04% |
| Dec 31, 2021 | 1.55M | 877.00K | 130.12% |
| Dec 31, 2020 | 674.00K | -43.00K | -6.00% |
| Dec 31, 2019 | 717.00K | -1.50M | -67.60% |
| Dec 31, 2018 | 2.21M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 86.55M |
| Retractable Technologies | 38.27M |
| Bionano Genomics | 28.51M |
| Jin Medical International | 20.69M |
| Nephros | 18.79M |
| Ekso Bionics Holdings | 12.80M |
| Milestone Scientific | 8.93M |
| Lucyd | 2.66M |
NXGL News
- 2 days ago - NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity - GlobeNewsWire
- 21 days ago - NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products - GlobeNewsWire
- 23 days ago - NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products - GlobeNewsWire
- 23 days ago - EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue - Benzinga
- 4 months ago - NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx - GlobeNewsWire
- 5 months ago - NEXGEL Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 8 months ago - NEXGEL to Report Second Quarter 2025 Financial Results on August 12th - GlobeNewsWire
- 8 months ago - NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement - GlobeNewsWire